India, July 15 -- Veradermics, Incorporated (MANE) on Wednesday reported positive topline results from its Phase 2 study of VDPHL01, an extended-release oral minoxidil formulation, in women with mild-to-moderate pattern hair loss.
Veradermics shares rose more than 4% in pre-market trading after closing at $110.17 on Tuesday.
The study showed that VDPHL01 produced clinically meaningful hair growth, with participants experiencing increases in non-vellus terminal hair counts after six months of treatment. Women receiving the 4.5 mg once-daily dose recorded an average increase of 22.7 hairs per square centimeter, while those receiving the same dose twice daily saw an increase of 23.3 hairs per square centimeter.
Patient-reported outcomes wer...